![dr. allan spreen high blood treaments dr. allan spreen high blood treaments](https://img.yumpu.com/3993616/1/500x640/anatomy-government-medical-college-and-hospital.jpg)
Song R, Oren DA, Franco D, Seaman MS, Ho DD.Strategic addition of an N-linked glycan to a monoclonal antibody improves its anti-HIV-1-neutralizing activity. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. 2015 7: 270ra4.Īndrews CD, Spreen WR, Mohri H, Moss L, Ford S, Gettie A, Russell-Lodrique K, Bohm RP, Cheng-Mayer C, Hong Z, Markowitz M and Ho DD. Long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenges. Cell 2016 165: 1621-1631.Īndrews CD, Yueh YL, Spreen WR, Bernard LS, Boente-Carrera M, Rodriguez K, Gettie A, Russell-Lodrigue K, Blanchard J, Ford S, Mohri H, Cheng-Mayer C, Hong Z, Ho DD and Markowitz M. Engineered bispecific antibodies with exquisite HIV-1 neutralizing activity. Huang Y, Yu J, Lanzi A, Andrews CD, Yao X, Sun M, Seaman MS, Padte NN and Ho DD.
![dr. allan spreen high blood treaments dr. allan spreen high blood treaments](https://i.pinimg.com/originals/69/32/1a/69321ae5139eb88ade49843cab2bc2f8.png)
Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of of anti-HIV-1 antibodies in vivo. Wang P, Gajjar MR, Yu J, Padte NN, Gettie A, Blanchard JL, Russell-Rodrique K, Liao LE, Perelson AS, Huang Y, and Ho DD. Potent neutralizing monoclonal antibodies directed to multiple epitopes on the SARS-CoV-2 spike. Liu L, Wang P, Nair MS, Yu J, Huang Y, Rapp MA, Wang Q, Luo Y, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Shapiro L and Ho DD. Please see our lab website for more information about our members and research. The laboratory is funded by two NIH grants to pursue the use of engineered antibodies as a part of an international effort to purge the viral latent reservoir, and by the Jack Ma Foundation to work on coronavirus projects. In 2020, since the COVID-19 pandemic began, the laboratory has begun investigating potential treatments and vaccines for SARS-CoV-2 coronavirus infection.
Dr. allan spreen high blood treaments trial#
The most promising neutralizing agent is a bispecific monoclonal antibody that entered a first-in-human clinical trial in 2019 with the support of the Bill & Melinda Gates Foundation. In parallel, the laboratory has also engineered potent antibodies that neutralize divergent strains of HIV. One such agent, cabotegravir, has been advanced into Phase-3 efficacy trials in high-risk populations, in collaboration with GlaxoSmithKline. The laboratory was the first to demonstrate protective efficacy of a long-acting antiretroviral drug as pre-exposure prophylaxis in rhesus macaques. However, non-vaccine approaches to block HIV transmission have shown considerable promise. A protective vaccine against HIV remains elusive despite concerted research efforts. This was the turning point in the AIDS pandemic, transforming an automatic death sentence into a manageable disease.įor the past decade and a half, the laboratory has shifted its research focus to developing strategies to prevent HIV transmission. These studies formed the foundation for a pioneering effort to treat HIV “early and hard” and demonstrated for the first time the durable control of HIV replication in patients receiving combination antiretroviral therapy.
Dr. allan spreen high blood treaments series#
In the mid 1990s, the laboratory conducted a series of human studies to elucidate the dynamics of HIV replication in vivo. The laboratory has been engaged in HIV research since the beginning of the AIDS pandemic, initially focusing on clinical virology and select topics in HIV pathogenesis. Member, American Academy of Arts & Sciencesįellow, American Association for the Advancement of ScienceĬlinical virology, HIV pathogenesis, prevention of HIV and coronavirus transmission, HIV and coronavirus vaccine development
![dr. allan spreen high blood treaments dr. allan spreen high blood treaments](https://nursingcrib.com/wp-content/uploads/2010/03/pregnant-blood-pressure-check-stock.jpg)
Professor of Microbiology & Immunology, Clyde '56 and Helen Wu Professor of Medicine and Director, Aaron Diamond AIDS Research Center